Skip to main content
Premium Trial:

Request an Annual Quote

Aquila-Histoplex Named ACD's First European RNAscope Certified Service Provider

NEW YORK (GenomeWeb) – Advanced Cell Dx today announced Edinburgh, Scotland-based CRO Aquila-Histoplex as the first accredited RNAscope Certified Service Provider in Europe.

Aquila-Histoplex, which specializes in histological and multiplex staining technologies, has more than two years of experience performing the RNAscope assay for the academic and commercial research sectors, the company said in a statement.

Mike Millar, CEO of Aquila-Histoplex, said in a statement that the certification would ensure that the company can provide its clients with the highest quality RNA in situ hybridization data and is "a perfect tool for completing our portfolio."

ACD's RNAscope technology is an automated multiplex chromogenic and fluorescent in situ hybridization platform capable of detecting and quantifying RNA biomarkers in formalin-fixed, paraffin-embedded tissues. It offers quantitative molecular detection along with morphological context in a single assay, the company said.

ACD, based in Hayward, Calif., develops cell and tissue-based analysis tools for personalized medicine.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.